Pascal Biosciences
Dr. Pearson is a retired professor in the Department of Biochemistry and Microbiology at the University of Victoria. He obtained his BSc in Microbiology and Ph.D. in Immunology from the University of British Columbia. After postdoctoral work at the Medical Research Council Laboratory in Cambridge, England, Dr. Pearson worked as a staff scientist in its Division of Cell Biology. Over the past decade, his research has focused on the translation of basic research discoveries into the application to clinical diagnostic medicine in both the developed and developing world. He currently serves on the boards of several private and public biotechnology companies.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Pascal Biosciences
Pascal Biosciences is a biotechnology company focused on advancing innovative approaches for the treatment of cancer including cannabinoid-based therapeutics and targeted therapies. The company’s leading cannabinoid portfolio comprises a small molecule therapeutic, ST-403, that is advancing into clinical trials for the treatment of glioblastoma, and an immuno-stimulatory molecule. In addition, Pascal Biosciences is developing a B-cell targeted antibody for acute lymphoblastic leukemia and an antibody for calcium channels expressed by the immune system.